Jeil Pharma Holdings
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Jeil Pharma Holdings is listed on KOSPI, South Korea's main stock exchange.
Its official filing does not provide sufficient detail in the available text to describe its specific products, services, or supply-chain role with confidence. The company name suggests a holding-company structure in a pharma-related field, but no product or operational details can be confirmed from the filing text provided.
Summary is AI-generated and may contain errors · figures from DART filings
Jeil Pharma Holdings in five facts
What does Jeil Pharma Holdings do?
Jeil Pharma Holdings is listed on KOSPI, South Korea's main stock exchange.
Where is Jeil Pharma Holdings listed and in which sector?
Jeil Pharma Holdings (Korean name: 제일파마홀딩스) trades under KRX code 002620 on KOSPI, the main board of the Korea Exchange. It is classified in the Industrials sector, Commercial Services.
How large is Jeil Pharma Holdings?
Its market capitalisation was US$87.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Jeil Pharma Holdings's latest annual revenue and operating profit?
For fiscal year 2025, Jeil Pharma Holdings reported revenue of US$496.3M, operating profit of US$29.2M and net income of US$26.2M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was down 15.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
Jeil Pharma Holdings declared a cash dividend of US$0.05 per share, equal to about 0.9% of the recent share price.
Dividend · Mar 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Jeil Pharma Holdings reported consolidated results for FY2025: revenue of US$455M (−15.8% year on year), operating profit of US$26.8M (from a loss a year earlier) and net income of US$24.1M (from a loss a year earlier).
Earnings · Feb 23